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UNIT A11.3Myocardial Perfusion and Viability
Rapid magnetic resonance imaging of the heart during the first pass of a bolus-injected
contrast agent can be used to assess myocardial perfusion (Manning et al., 1991; Rossum
et al., 1990; Wilke et al., 1994; Wilke et al., 1993). In this context, the term perfusion
refers to transport of the contrast agent into myocardial tissue by blood flow, distribution
in the tissue, and washout. Following the course of enhancement after injection of an
extracellular MR contrast agent such as Gd-DTPA (gadolinium diethylenetriamine pen-
taacetic acid) provides a means to determine myocardial blood flow. The rate of contrast
enhancement depends on the rate of transport of the contrast agent through a tissue region,
indicating sensitivity to the level of tissue blood flow. Assessment of perfusion over the
entire heart with MRI is generally accomplished by 2-dimensional imaging of multiple
slices. Cardiac motion appears frozen if the acquisition time for each image is short on
the time scale of a heart beat, and if the image acquisition is synchronized to the heart
rhythm.
Compared with other organs, the heart has a relatively high resting blood flow and blood
volume on the order of ∼1 ml/min per gram of tissue and 0.1 ml per gram of tissue,
respectively. The wash-in of an injected contrast agent takes, under normal conditions,
only a couple of heart beats. This determines the required temporal resolution for dynamic
first pass studies. Multislice coverage of the heart and sequential imaging with a temporal
resolution of ∼1 image per heart beat for each slice location can be met with rapid
T1-weighted, gradient echo imaging techniques. T1-weighted imaging is the method of
choice for imaging of perfusion in the heart. Contrast agent bolus dosages typically used
for T1-weighted myocardial perfusion imaging of the heart give rise to a several-fold signal
intensity increase over the precontrast level of signal intensity. T2*-weighted imaging is
by definition sensitive to magnetic susceptibility changes produced by the introduction
of paramagnetic contrast agents. T2*-weighted imaging is more prone to susceptibility-
induced artifacts–the arrival of the contrast agent in the ventricular cavity gives rise to a
marked drop of T2*-weighted signal intensity that extends into myocardial tissue.
Extracellular contrast agents such as Gd-DTPA, are commonly used for MRI perfusion
studies. Extracellular contrast agents cross the cell membrane only after severe myocar-
dial injury and the loss of myocardial viability has occurred (Judd et al., 1995; Kim et al.,
1996; Lima et al., 1995; Tong et al., 1993a,b). The distribution volume of an extracellular
contrast agent is larger in injured tissue than in normal tissue. Given sufficient time, an
extracellular contrast agent reaches an approximate equilibrium distribution where the
contrast enhancement of tissue relative to the contrast enhancement in the ventricular
blood pool is proportional to the distribution volume (Pereira et al., 1996; 1999). Loss of
viability and leakage of the contrast agent into the cell results in T1-weighted signal
hyperenhancement.
Both first pass perfusion studies and imaging of delayed hyperenhancement can be
combined in one patient exam. The MRI protocols for myocardial perfusion and viability
assessment are presented together in this unit due to the complimentary information that
is obtained with both protocols. Also, the imaging techniques used for both protocols are
closely related. Basic Protocol 1 should be used in patients with symptoms of coronary
artery disease or ischemic cardiomyopathies. Basic Protocol 1 assesses the functional
severity of coronary artery lesions. Basic Protocol 1 takes ∼30 min, including the time
for patient preparation and study set-up. If imaging of perfusion during pharmacological
stress is included, the duration is increased to ∼45 min. Basic Protocol 2 should be used,
in addition to Basic Protocol 1, when a patient presents with symptoms of myocardial
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infarction or post-coronary revascularization to determine the presence and extent of
nonviable myocardium. Basic Protocol 2 adds an additional 20 min for the completion of
the examination.
BASIC
PROTOCOL 1
IMAGING MYOCARDIAL PERFUSION DURING FIRST-PASS
CONTRAST-ENHANCEMENT
By its very nature, the short repetition times and high bandwidths of fast imaging
techniques used for myocardial perfusion imaging can create a challenge for achieving
an acceptable signal-to-noise ratio (SNR) that allows reliable interpretation of the images.
It is, therefore, generally only possible to obtain acceptable SNRs at field strengths of
≥1.0 T. The only exception occurs with echo-planar imaging sequences, which may work
better at lower field strengths due to the inherent reduction of T2* artifacts at lower field
strengths. Single-shot echo-planar imaging (EPI) techniques applied to the heart are more
prone to image artifacts than multi-shot EPI techniques or segmented gradient-echo/EPI
sequences. The latter can be used for cardiac perfusion imaging to improve the speed of
image acquisition, without incurring a significant penalty in image quality.
Fast T1-weighted imaging sequences, such as spoiled gradient-echo imaging with TR’s as
short as 2 msec and a magnetization preparation for T1-weighting, are applied to image
the contrast-enhancement during the first pass of the injected contrast agent. Once the
limits of gradient system performance have been reached with gradient-echo imaging,
multi-shots between conventional gradient echo and echo-planar imaging provide an
additional boost in image acquisition speed. Instead of reading out a single gradient echo
after each slice-selective radio-frequency excitation pulse, segmented pulse sequences
create a train of typically 3 to 5 gradient echoes after each radio-frequency excitation
pulse. Reading out the closely spaced gradient echoes without the need to (re)apply a slice
selective radio-frequency pulse before each gradient echo boosts the rate of image
acquisition.
The image intensity obtained with an inversion-recovery (IR) or saturation-recovery-pre-
pared fast gradient echo sequence is strongly T1-weighted. With an IR preparation the
signal intensity depends not only on the inversion time after the preparation but also on
the state of the magnetization before the inversion pulse is applied. During rapid serial
imaging with electrocardiograph-triggered (ECG-triggered) IR-prepared gradient echo
sequences, therefore, the signal intensity depends on the heart rate. A saturation recovery
magnetization preparation consists of a non-slice selective 90° radio frequency pulse,
followed by a gradient crusher pulse to dephase the transverse magnetization (Tsekos et
al., 1995). Driving the magnetization into a well-defined state, with all magnetization
components nulled or dephased, allows one to obtain a T1-weighted gradient-echo signal
that is independent of the duration of an any previous relaxation recovery delay. The
saturation recovery preparation prevents modulation of the image intensity, when the
ECG-triggered image acquisition rate varies due to fluctuations in heart rate. Saturation-
recovery prepared gradient echo imaging is therefore preferred over the inversion-recov-
ery preparation when heart rate variations, or an unreliable ECG trigger are of concern
(Tsekos et al., 1995). Furthermore, multi-slice imaging is more easily implemented with
a saturation-recovery preparation than with an IR magnetization preparation (Wilke et al.,
1997).
Rapid contrast agent administration is crucial for assessing myocardial perfusion with
contrast agents as this improves the sensitivity for detecting changes of myocardial blood
flow (Kroll et al., 1996). The goal is to assure that the primary bottleneck to the rate of
contrast enhancement is the rate of transport of contrast agent through myocardial tissue,
and not the rate at which the contrast agent is injected. The regional image intensity
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contrast enhancement should ideally be proportional to the contrast agent concentration.
Such an approximate linear relationship between regional signal intensity and contrast
agent concentration is only observed at lower contrast agent dosages–typically, <0.05
mmol/kg of Gd-DTPA for fast, IR-prepared gradient-echo sequences (TR ≤3 msec; TE ≤2
msec; Jerosch-Herold et al., 1998). A more marked contrast enhancement can be obtained
with higher contrast agent dosages, but then the kinetics of the contrast agent, and the
correlation of contrast enhancement with tissue blood flow can not be assessed in a strict
quantitative manner. The choice of contrast agent dosage is therefore in part dictated by
the quantitative requirements for a perfusion study.
Table A11.3.1 lists the required equipment for first-pass perfusion imaging.
NOTE: Adenosine or dipyridamole is not FDA (Food and Drug Administration)-approved
for use with MRI. Gd-DTPA is not FDA-approved for cardiac imaging. While any
physician can use any drug already FDA-approved for another reason off-label, the
protocol described herein suggests the off-label use of two drugs simultaneously. This
protocol has been developed for research only.
Materials
Normal saline (0.9% NaCl), sterile
Extravascular GD-DTPA contrast agent (e.g., Magnevist or Omniscan)
16-G i.v. needle and injection line
Disposable syringes for power injector
Set up patient and equipment
1. The same precautions as with any other MRI exam should be followed when
preparing a patient for an MRI examination of myocardial perfusion. Check for
possible counter-indications and for ferromagnetic implants. For patients with heart
Table A11.3.1 Equipment Parameters for First Pass Perfusion Imaging
Coil type Quadrature phase-array torso coil.
Gradient coil strength 24 mT/m (or higher if the system permits)
Cardiac gating Yes, fiber-optic systems are preferred for studies
performed during pharmacologic stress or
vasodilation
Peripheral gating For safety only
Respiratory gating No
Respirator If required by patient
Oxygen If required by patient
Breath-holding Optional
Motion cushions Can be used for patient comfort
Use of contrast agents Extracellular or intravascular contrast agent
administered with power injector through
intravenous (i.v.) needle in antecubital vein
Power injector Important for rapid and reproducible
administration of contrast agent
Infusion pump Required for pharmacological stress or
vasodilation
Monitoring equipment Heart rate, oxygen saturation, and blood pressure
should be monitored with MRI-compatible
equipment. EKG rhythm strip monitoring should
be available if pharmacologic stress or
vasodilation is planned.
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disease, check heart rate, blood pressure, and other vital signs while the patient
undergoes the MRI examination. Emergency equipment such as a defibrillator, and
emergency medications for treating cardiac arrests (e.g., epinephrine) should be
nearby. If measurement of perfusion during vasodilation is being contemplated, a
cardiac nurse or a cardiologist should be present to monitor the patient during the
examination, and be prepared to initiate emergency procedures if an adverse event
occurs.
Generally, standard screening forms are used for all patients scanned in a magnetic
resonance system.
Patients may be accompanied into the magnet room by a friend or family member, who can
sit in the room during the scan and comfort the patient as needed. This companion must
be screened as well to ensure the absence of loose metal objects on the body or clothing.
2. If the procedure is a research protocol, have the patient sign any necessary consent
form.
3. Have the patient remove all jewelry and change into a gown to eliminate any metal
that might be found in clothing.
4. Have the patient wash off any mascara and other makeup to avoid local tissue heating
and image artifacts.
5. Inform the patient about what will occur during the procedure, what he or she will
experience while in the magnet, and how to behave, including the following:
a. If earphones or headphones are used to protect the ears from the loud sounds
produced by the gradients, the patient will be asked to wear these, but will be able
to communicate with you at any time during the imaging.
b. The patient will be given a safety squeeze-bulb or similar equipment to request
assistance at any time (demonstrate how this works).
c. For good results, the patient should not talk, and should avoid or minimize
swallowing or other movement, during each scan–i.e., as long as the banging
sounds continue. Between scans, talking and swallowing are allowed in most
cases, but should be avoided when comparative positional studies are being
performed; the patient will be informed when this is the case.
d. Nevertheless, the patient may call out at any time if he or she feels it necessary.
6. An intravenous (i.v.) line should be started before the examination for administration
of the contrast agent. Myocardial perfusion studies require either a central or
peripheral injection of contrast agent, preferably with a power injector at a rate of 5
to 10 ml/sec. A venous catheter line advanced through the antecubital vein to the
superior vena cava, or a 16-G needle in an antecubital vein, will allow injection of
the contrast agent as a compact bolus. Use a dual-port connector with the needle to
allow injection of contrast agent and infusion of pharmacological agent, such as
adenosine.
7. If a power injector is used, the contrast agent and saline should be loaded under sterile
conditions into the proper (disposable) syringes of the power injector. Great care
should be taken to expel all air bubbles from the reservoirs and catheter lines. Luer
fittings should be examined to ensure that they are secure and tight. Injection dosage
and rate should be set appropriately. Newer power injector systems have touch-sen-
sitive liquid crystal display (LCD) screens to set the injection parameters. Contrast
agent injections should generally be followed without delay by an injection of
physiologic saline solution to assure that the entire contrast agent dosage is injected
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into the vein. A constant saline drip before and after bolus administration is recom-
mended to keep i.v. injection lines open.
For older power injector models that cannot be brought near the magnet, the contrast agent
is preloaded through an i.v. catheter and a long i.v. line is connected to a remotely
positioned power injector.
8. Position the patient supinely on the scanning table. Provide him/her with a cushion
under the legs for comfort.
9. Place the ECG electrodes around the heart with ≤4 in. of separation between them.
This results in an improved quality of the ECG signal and more reliable triggering
of the pulse sequence. Align the ECG wires parallel to the magnetic-flux lines of the
static magnetic field. Conductive cables should not cross inside the bore, and they
should also be kept away from the sides of the bore. These precautions are necessary
to minimize the risk of burns due to radio-frequency power deposition.
ECG triggering is often a source of problems in cardiac MRI examinations due to
degradation of the ECG signal by superimposed voltages that are generated by blood flow
through the great vessels while the patient is positioned in a strong magnetic field. Special
MR-compatible physiologic recorders, which can be interfaced with the MRI scanner, often
use customized ECG electrodes and proprietary filtering techniques to reduce artifacts in
the ECG.
The ECG electrodes may be placed on the chest or back. Placing them on the chest is best
for monitoring, but in this position the ECG signal is more susceptible to artifacts from
breathing motion, as well as image artifacts from the leads affecting the right ventricle.
The dry rub method improves electrode contact to the skin and reduces contact resistance.
If the baseline of the ECG moves up and down with respiration, then the ECG leads need
to be moved up higher on the chest. Asking the patient to avoid strong breathing motion
can help. Reducing the distance between the ECG leads can reduce interference from
switching of the gradient coils.
The quality of the ECG signal is normally just sufficient for counting the heart rate and
triggering the MR image acquisition with the R wave of the QRS complex, but not good
enough to diagnose the on-set of ischemia from changes in the ST segment. (Q, R, S, and
T are the standard nomenclature for distinctive features on the ECG trace that correspond
to well defined events during the cardiac cycle. The reader is referred to introductory
physiology textbooks for further details.) It is therefore important to supplement the ECG
signal with measurements of the arterial oxygen saturation and blood pressure, especially
if the patient will be undergoing a stress protocol or pharmacological vasodilation in the
magnet. If pharmacologic stress or vasodilation is planned, fiber optic leads that reduce
the signal artifact caused by patient motion and radiofrequency interference is preferred.
A rhythm strip should be run between each sequence acquisition during adenosine,
dipyridamole, or dobutamine administration. While ischemic changes cannot be moni-
tored, the strips can be monitored for heart block or arrhythmias.
10. Wrap blood pressure cuff around the arm to monitor blood pressure. MRI compatible
monitoring systems use a pump that inflates and deflates the blood pressure cuff at
predefined time intervals or when the technologist manually initiates a blood pressure
measurement. Place a fiber optic sensor on the patient’s finger to measure the arterial
oxygen saturation. Take note of the baseline heart rate, systemic blood pressure, and
oxygen saturation.
11. Use a dedicated cardiac coil for these studies to maximize the achievable SNR. Center
the coil at the level of the heart, or over the patient’s heart, if a relatively small surface
coil is used.
In many cases phase-array coils with anterior and posterior elements fitted under the
patient and over the patient’s chest work best for this purpose.
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12. Instruct the patient on the procedure for breath-holding during the MRI examination.
First pass studies can be performed with the patient breathing normally, although the
absence of breathing motion facilitates interpretation of the images.
13. Provide the patient with headphones or earplugs. The intercom equipment should be
used during the MRI study to guide the patient and assure his/her cooperation. Alert
the patient before an i.v. injection or infusion, particularly in cases where the infusion
of a pharmacological agent induces hemodynamic changes. Tell the patient to signal
any discomfort or the onset of pain. Communication with the patient is important for
the success and safety of the study!
14. Position the patient in the magnet such that the heart is in the center of the magnet.
15. Check that a strong ECG R-wave is received before proceeding. Otherwise the ECG
leads have to be reconfigured to produce a more prominent R-wave peak.
Sequence 1: Scout imaging of the heart
16. Acquire a transverse scout with a fast gradient echo sequence, preferably with dark
blood preparation for better visualization of ventricular cavities. Typical sequence
parameters for such a pulse sequence are listed in Table A11.3.2.
17. Oblique pseudo-long axis scout: Prescribe on the previous image a slice through the
middle of the left ventricle and acquire an image for this view as localizer.
18. Horizontal long axis scout: Prescribe on previous scout, a slice parallel to the septum,
centered in the LV cavity, positioned from the LV apex, through the mid portion of
the mitral valve. Acquire image. An example of the images obtained by following
steps 16 to 18 is shown in Figure A11.3.1.
Table A11.3.2 Primary Clinical Imaging Parameters for Sequence 1 (Pilot
Scan)
Patient position Supine
Scan type Fast gradient echo with dark
blood preparation
Imaging plane (orientation) Transverse, pseudo-long axis,
double oblique short axis
Central slice or volume center Laser light centered on coil center
(at heart)
Echo time (TE) 2.3 msec
Repeat time (TR) 5 msec
Flip angle (FA) 10°
Fields of view (FOVx, FOVy) 400 mm, 400 mm
Resolution (∆x, ∆y) 1.56 mm, 3.13 mm
Number of data points collected (Nx, Ny ) 256, 128
Display matrix (Dx, Dy ) 256, 256
Slice thickness (∆z) 10 mm
Number of slices 1
Slice gap Not applicable
Number of acquisitions (Nacq) 1
Swap read and phase encoding No
Slice location Not applicable
Saturation pulses Not applicable
Scan time ∼600 msec
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19. Acquire one mid-ventricular short axis view as second localizer. This second localizer
is used in setting up sequences 2 and 3 to determine the smallest possible field of
view dimensions that do not cause wrap-around that obscures the view of the heart.
Sequence 2: Magnetization-prepared, T1-weighted FLASH (fast low angle shot)
perfusion imaging
20. Call up the rapid, multi-slice T1-weighted spoiled gradient-echo imaging as described
in Table A11.3.3. Either a saturation-recovery or an inversion-recovery preparation
can be used, although the former appears to be more advantageous for multi-slice,
arrhythmia-insensitive imaging (Tsekos et al., 1995; Wilke et al., 1997). Table
A11.3.4 gives the parameters for an inversion-recovery (IR) prepared echo-planar
sequence, that can be used as an alternative to the sequence in Table A11.3.3 for
myocardial perfusion imaging. Figure A11.3.2 shows a diagram of the pulse sequence
protocol.
IR-prepared segmented echo-planar pulse sequences represent a useful alternative on some
scanners for first pass perfusion imaging (Ding et al., 1998; Fischer and Lorenz, 1997;
Reeder et al., 1999). Instead of reading out all image data after a single radio-frequency
(RF) pulse as is done in single-shot EPI, in multi-shot sequences RF pulses are applied
repeatedly to produce short echo trains. The echo train length after each radio-frequency
pulse is 4 to 6 echoes, and the optimal TR is on the order of 10 to 15 msec at 1.5 T (Epstein
and Arai, 2000). The pulse sequence is optimized for high temporal resolution (∼6 to 7
slices per 2 R-to-R intervals). A slice-selective inversion-recovery magnetization prepara-
tion is applied for each slice. For multi-slice acquisitions, the slice-selective IR preparation
for a given slice can be applied right before the EPI readout for a preceding slice to
maximize the efficiency in image acquisition while maintaining a sufficiently long inversion
time to optimize the T1-weighting. For example, the IR preparation pulse for slice 2 is
applied just before the EPI readout of slice 1. This construction constrains the choice of TI
but in practice the duration of the EPI read-out matches well the optimal TI values. Call
up the rapid, multi-slice, T1-weighted, multi-shot echo-planar imaging sequence as de-
scribed in Table A11.3.3.
21. Preset the contrast agent injection dosage at ∼0.04 to 0.1 mmol/kg times patient body
weight in kilograms divided by the concentration of Gd-DTPA when TR/TE/FA of the
saturation-recovery prepared spoiled gradient echo sequence are on the order of 2.4
msec/1.2 msec/18°, respectively. Injection rate depends on the size of the i.v. needle
or catheter but should be on the order of 5 ml/sec for a compact bolus.
It is useful to remember that the injection rate specified on the control panel of the injector
is often a nominal injection rate that is not reached if the catheter size is too small.
Figure A11.3.1 Scout images for transverse (step 16), pseudo-vertical long axis (step 17), and pseudo-horizontal long
axis (step 18) in left-to-right order. The images were acquired with a fast steady-state free-precession (SSFP) scout imaging
technique (“true FISP”), which was used because of the excellent definition of anatomical structures that is achieved with
this technique. The use of SSFP imaging is currently limited to MRI systems with high-performance gradient systems. The
thick white lines denote the image plane orientation for the next scout image to the right.
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22. Adjust the number of phase encoding steps (Ny) to a value between 80 and 120 such
that the combination of phase encoding steps and the number of slices result in an
image acquisition time that matches the heart rate. Maintain an in-plane spatial
resolution of <3 mm.
For a heart rate of 60 beats/min (R-to-R interval of 1000 msec) the repetition time (TR)
times the number of phase encoding steps (Ny) plus the time for the magnetization
preparation (TI) determine the time required to image one slice (TACQ): TACQ = Ny*TR + TI.
This time (TACQ) multiplied by the number of slices should be less than the R-to-R interval
to maintain a temporal resolution of 1 image per heart beat for each slice location. The
idle time at the end of the R-to-R interval should be ≥40 msec to anticipate possible small
increases in heart rate during the image acquisition that could cause intermittent changes
in rate of image acquisition.
Table A11.3.3 Primary Clinical Imaging Parameters for Sequence 2 (First
Pass Perfusion, T1-weighted FLASH Variant)
Patient position Supine
Scan type Rapid serial, multislice 2-D
gradient echo imaging with
magnetization preparation for
T1-weighting
Imaging plane (orientation) Double oblique short axis view
Central slice or volume center Centered over the heart
Echo time (TE) 1.2 msec, or as short as possible
(usually <2 msec)
Repeat time (TR) 2.4 msec or short as possible
(usually <3 msec)
Inversion time (TI) 10 msec for saturation recovery
preparation and 100–150 msec for
inversion recovery preparation
Flip angle (FA) 15°–18°
Fields of view (FOVx, FOVy) 320 mm, 320r mm, with r = 6/8
(rectangular field of view)
Resolution (∆x, ∆y) 2.50 mm, 2.76 mm
Number of data points collected (Nx, Ny) 128, 118r, with r = 6/8
(rectangular field of view)
Display matrix (Dx, Dy) 128, 128
Slice thickness (∆z) 10 mm
Number of slices 2–6, or as many as needed to
cover the heart from base to apex
Slice gap 0.3–0.5 of slice thickness
Number of acquisitions (Nacq) 1
Number of repetitions 40 (number of serial images for
first pass study)
Swap read and phase encoding Only if this reduces aliasing
artifacts and allows reduction of
FOV
Slice location User define short axis locations
between base and apex
Saturation pulses No
Slice series Interleaved
ECG gating Yes
Scan time ∼40 R-to-R intervals
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23. Use the scout images acquired earlier to prescribe the slices for the perfusion study.
Except for the visualization of apical perfusion defects, double oblique slices that
give a short axis view of the heart are recommended for this study. For multi-slice
acquisitions, set the gap between slices to 30% to -50% of the chosen slice thickness.
An arbitrary gap thickness may be chosen if maintenance of adequate temporal resolution
(1 image per 1 to 2 heart beats) allows only imaging of 2 to 3 slices. The choice of slice
locations is often guided by findings from wall-motion studies that are performed before-
hand. Slice positions are then chosen based on the location of wall-motion defects.
24. Minimize the fields of view without causing aliasing (“wrap-around”) artifacts. Use
the double oblique short-axis localizer (see sequence 1) for this purpose. Choose the
read-out direction parallel to the chest wall as this reduces the possibility of aliasing
and other artifacts. See Figure A11.3.3 showing perfusion images for three slice
locations.
Table A11.3.4 Primary Clinical Imaging Parameters for Sequence 2 (First
Pass Perfusion, Multishot EPI variant)
Patient position Supine
Scan type Rapid, IR-prepared, segmented
(multi-shot) EPI sequence
Imaging plane (orientation) Double oblique short axis view
Central slice or volume center Centered over the heart
Echo time (TE) As short as possible (usually <2
msec)
Echo train length (ETL) 4–6
Repeat time (TR) As short as possible (usually <15
msec)
Inversion time (TI) 100–200 msec
ECG trigger delay Minimum
Flip angle (FA) 20°
Fields of view (FOVx, FOVy ) 360 mm, 360r mm, with r = 3/4
(rectangular field of view)
Resolution (∆x, ∆y) 2.80 mm, 2.80 mm
Number of data points collected (Nx, Ny ) 128, 128r, with r = 3/4
(rectangular field of view)
Display matrix (Dx, Dy ) 128, 128
Slice thickness (∆z) 8 mm
Number of slices 3–6, or as many as needed to
cover the heart from base to apex
Slice gap 0.25 of slice thickness
Number of acquisitions (Nacq) 1
Number of repetitions ∼40
Swap read and phase encoding Only if this reduces aliasing
artifacts and allows reduction of
FOV
Slice location User define short axis locations
between base and apex
Saturation pulses No
Slice series Interleaved
ECG gating Yes
Scan time ∼40 R-to-R intervals
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R
T
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R
Multislice SR-Prepared FLASH
Slice  1 Slice  2 Slice  1 Slice  2
Figure A11.3.2 Schematic sequence diagram of multislice perfusion imaging sequence with
nonslice-selective saturation-recovery (SR) preparation before each FLASH readout. The delay
between the SR preparation and the FLASH readout can be kept as short as 10 msec and still
provides good T1-weighting of the signal intensity. By comparison, an inversion recovery preparation
requires a relaxation delay (TI) of ∼100 msec. A slice-selective magnetization-preparation would
lead to modulation of the signal intensity from spins flowing into the magnetization-prepared volume.
A nonslice-selective preparation pulse eliminates this flow-dependent modulation of the signal
intensity.
Figure A11.3.3 Selected frames from a multislice first pass perfusion study acquired in a 53 year
old male patient with a scarred infarct in the inferior wall. The images are arranged in separate rows
for each slice position, and in each row the images show the sequential appearance of the contrast
agent bolus in the right ventricle, the left ventricle, and enhancement of myocardial tissue. Images
were acquired while the patient held his breath. The images in this example have not been cropped
and they illustrate how the rectangular field of view is adjusted to avoid wrap-around in the phase
encoding direction, which can otherwise obstruct the view of the heart.
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25. Start the pharmacological stress protocol before the contrast injection if this is part
of the study. Note that adenosine requires 3 min to reach steady state. Slowly
increment the dosage of the pharmacological agent, such as dipyridamole or adeno-
sine if induction of hyperemia is desired. Monitor the patient’s blood pressure and
heart rate. Run a rhythm strip between each dose increase and between each sequence
acquisition. Observe for an atrial block or any other abnormalities in heart-rhythm.
Discontinue the infusion immediately in case problems develop. Have aminophylline
ready in case dipyridamole was used, and it becomes necessary to relieve or reverse
its effects.
The first pass measurement during pharmacological stress can be repeated at 10 to 15 min
after a previous first pass study, for example, a baseline “rest” study. The first pass studies
can be repeated up to 3 times with a dosage of 0.03 to 0.05 mmol/kg of Gd-DTPA and with
the sequence parameters shown in Table A11.3.2.
The effect of potent coronary vasodilators such as adenosine or dipyridamole is adequate
for perfusion imaging when the heart rate increases by 10 bpm and diastolic blood pressure
decreases by 10 mm Hg. The patients often feel some chest pressure and slight discomfort
during vasodilation with adenosine or dipyridamole. Patients on beta-blockers will not
show a significant rise in heart rate during i.v. adenosine or dipyridamole.
Figure A11.3.4 Magnified multislice perfusion images in a patient with an inferior perfusion defect.
The perfusion defect results in a reduced and slowed contrast enhancement after the first pass
through the left ventricle. Patient had shown a fixed defect in the inferior wall segment on single plot
on emission computed tomography (SPECT).
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26. The power-injector should be armed, i.e., readied for injection.
27. If breath-holding is used, the patient should be asked to take a deep breath and hold
his/her breath.
This pulse sequence does not necessarily require breath-holding to avoid breathing motion
artifacts in the image. It is nevertheless recommended that the patient holds his/her breath
as long as possible so that the position of the heart appears fixed in consecutive images.
28. Begin the scan as soon as the patient starts to hold his/her breath. Listen for regular
sounds from the gradients that indicate regular triggering of the pulse sequence by
the ECG. The contrast agent injection should be started after acquisition of 3 to 4
“baseline” images.
Process data and view for sequence 2
29. View the acquired series of sequential images in cine mode to determine that the
contrast agent bolus was successfully injected. It is important to ascertain that a
sufficient number of images were acquired to track the passage of the contrast agent
through the first pass at least to the beginning of recirculation in the left ventricular
cavity. This initial visual assessment should be performed immediately after image
acquisition. Absence of any contrast enhancement due to a problem with the contrast
agent injection or other malfunctions should be corrected and the study repeated no
earlier than 5 min after the previous contrast injection.
The initial visual assessment already provides an impression about any spatial heteroge-
neities and temporal delays in myocardial contrast enhancement. This may indicate
regional impairments in myocardial blood flow, but potential pitfalls in interpretation like
a drop-off in signal intensity due to an inhomogeneous surface coil profile need to be kept
in mind. Figure A11.3.4 shows an example from a “rest” study in a patient with a fixed
perfusion defect in the inferior wall. Pharmacological vasodilation is necessary to detect
mild to moderate perfusion defects.
BASIC
PROTOCOL 2
IMAGING MYOCARDIAL VIABILITY
With imaging of hyperenhancement, the requirements for very short image acquisition
times can be somewhat relaxed to improve the signal-to-noise ratio (SNR) and the spatial
resolution. Nevertheless the avoidance of image artifacts from cardiac motion still
requires that the image acquisition be performed only during a relatively small fraction
of the cardiac cycle, and preferably during the most quiescent diastolic period of the
cardiac cycle. The most successful techniques employed for imaging of delayed (hyper-)
enhancement in injured and/or infarcted myocardium have resorted to the segmented
acquisition of the k-space data, but are otherwise very similar to the imaging techniques
employed for first pass imaging. The goal is to maximize the T1-weighted contrast, with
minimum interference from T2* effects and cardiac motion.
T1-weighted imaging is applied ∼10 to 20 min after injection of the contrast agent to
identify severely injured, nonviable myocardial segments (Tong et al., 1993a). For delayed
enhancement studies, one is interested in the imaging differences of distribution volume
of the contrast agent. By the time the contrast agent distribution is in a semi-equilibrium,
the duration of the contrast agent injection has no noticeable effect, unless prolonged over
minutes. Hand injections of the contrast agent are therefore acceptable. Image sequences
that employ segmented acquisitions of k-space data require breath-holding for the
duration of each image acquisition to achieve optimal image quality.
Timing for imaging of hyperenhancement is an important aspect of this study. The time
to reach 90% of equilibrium concentration depends on the distribution volume, but
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generally does not >15 min (Tong et al., 1993a). Larger infarcts can show a core zone that
initially lacks enhancement even at ≥5 min after contrast agent injection. This phenome-
non, linked to microvascular obstruction, was shown to carry a graver prognosis for the
patient, than if the core no-enhancement zone was absent (Rochitte et al., 1998; Wu et al.,
1998b). Microvascular obstruction creates a severe bottleneck for the delivery of contrast
into the affected zone, but given sufficient time a central no-enhancement zone will also
display hyperenhancement compared to remote zones (Wu et al., 1998a). The observation
of hypoenhancement and hyperenhancement will depend on the delay between contrast
agent injection and acquisition of the images. A hypoenhancement zone with a surround-
ing hyperenhanced rim indicates that contrast agent has not yet reached the core zone. A
dark core zone can not simply be interpreted as a zone with reduced distribution volume.
The measurement should be repeated after an additional delay.
In cases where relatively low dosages of contrast agent are used for the first pass study,
one would follow the first pass study with a second and higher dosage injection of contrast
agent to image the late-enhancement. Typical dosages used for imaging of viability are
on the order of 0.1 to 0.2 mmol/kg of Gd-DTPA. For example, with a bolus dosage of
0.05 mmol/kg of Gd-DTPA for a first pass study an additional dosage of 0.15 mmol/kg
of Gd-DTPA contrast agent should be injected for imaging of viability. The time delay
after injection of the contrast agent and before imaging of the delayed hyperenhancement
should be used for optimizing the T1-contrast through adjustment of the image parameters,
primarily the inversion time TI.
Set up patient and equipment
1. The same precautions as with any other MRI exam should be followed when
preparing a patient for an MRI examination of myocardial viability (see Basic
Protocol 1). This includes checking for possible counter-indications and for ferro-
magnetic implants. For patients with suspected acute myocardial infarction, heart
rate, blood pressure, and other vital signs should be checked while the patient
undergoes the MRI examination. Emergency equipment such as a defribillator, and
emergency medications for treating cardiac arrests (e.g., epinephrine) should be
nearby.
2. An i.v. injection line for administration of contrast agent should be started before the
examination.
3. Position the patient supinely on the scanning table. Provide him/her with a cushion
under the legs for comfort.
4. Place the ECG electrodes around the heart with ≤4 in. of separation between each
one. This results in an improved quality of the ECG signal and more reliable
triggering of the pulse sequence. Align the ECG wires parallel to the magnetic flux
lines of the static magnetic field. Do not cross the conductive cables inside the bore,
and also keep away from the sides of the bore.
These precautions are necessary to minimize the risk of burns due to radio-frequency power
deposition.
ECG triggering is often a source of problems in cardiac MRI examinations due to
degradation of the ECG signal by superimposed voltages that are generated by blood flow
through the great vessels while the patient is positioned in a strong magnetic field. Special
MR-compatible physiologic recorders, which can be interfaced with the MRI scanner, often
use customized ECG electrodes and proprietary filtering techniques to reduce artifacts in
the ECG.
The ECG electrodes may be placed on the chest or back. Placing them on the chest is best
for monitoring, but in this position the ECG signal is more susceptible to artifacts from
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breathing motion, as well as artifacts from the leads affecting the right ventricle. The dry
rub method improves electrode contact to the skin and reduces contact resistance. If the
baseline of the ECG moves up and down with respiration, then the ECG leads need to be
moved up higher on the chest. Asking the patient to avoid strong breathing motion might
help. Reducing the distance between the ECG leads might reduce interference from
switching of the gradient coils.
5. Use a dedicated cardiac coil for these studies to maximize the achievable signal-to-
noise ratio. Center the coil at the level of the heart, or over the patient’s heart, if a
relatively small surface coil is used.
In many cases phase-array coils with anterior and posterior elements fitted under the
patient and over the patient’s chest work best for this purpose.
6. Instruct the patient on the procedure for breath-holding during the MRI examination.
Breath-holding durations are relatively short (i.e., ∼10 sec) for T1-weighted imaging
of viability with segmented k-space acquisition, as described below.
7. Provide the patient with headphones or earplugs. Tell the patient how to communicate
to the persons performing the exam while he/she lies in the magnet. The intercom
equipment should be used during the MRI study to guide the patient and assure his/her
cooperation.
8. Position the patient in the magnet such that the heart is in the center of the magnet.
9. Check that you receive a strong R-wave before proceeding. Otherwise the ECG leads
have to be reconfigured to produce a more prominent R-wave peak.
10. Run the scout sequence as listed in sequence 1 of Basic Protocol 1.
Sequence 3: T1-weighted gradient-echo imaging with segmented acquisition
11. Call up the protocol with a pulse sequence for rapid, T1-weighted imaging as
described in Table A11.3.5. The parameters in Table A11.3.5 are for an ECG-triggered
FLASH sequence with segmented acquisition of k-space lines (33 lines per segment)
and a non-slice selective inversion recovery (IR) magnetization preparation (Simon-
etti et al., 2000). Figure A11.3.5 shows a pulse sequence diagram that illustrates the
acquisition technique and acquisition parameters.
The IR magnetization preparation should be repeated before each k-space acquisition. For
the parameters listed in Table A11.3.5, and a contrast agent dosage of 0.2 mmol/kg, one
should use an inversion time (TI) of 150 msec as starting value. TI refers to the delay between
the inversion pulse and the acquisition of the first phase-encoded line of a segment, as
illustrated in Fig. A11.3.5. The definition of TI can vary between different sequences and
is also manufacturer-dependent. It may, for example, also refer to the time between the
inversion pulse and the acquisition of the central k-space line of each segment. TI needs to
be adjusted by the user to null the signal from presumably normal myocardium, and to
maximize the differential contrast enhancement of injured and non-viable myocardium. The
protocol produces best results if the patient holds his breath during image acquisition.
12. A delay of at least 2 heartbeats should follow the acquisition of each k-space segment
to allow for relaxation of the magnetization before the next inversion-recovery
preparation is applied. Without a delay the observable contrast enhancement is
reduced.
As with all breath-hold sequences, the adjustment of the total number of phase encoding
steps, the relaxation delay after acquisition of a k-space segment and the number of
averages should result in a total acquisition time that is within a comfortable breath-hold
duration.
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13. If the patient can not hold his/her breath, the number of acquisitions (or number of
excitations – NEX) needs to be set to a value of ≥3 to average out respiratory motion.
The number of averages can be <3 if respiratory gating can be used.
14. Use the scout images acquired earlier to prescribe the slice positions for imaging of
delayed hyperenhancement.
Imaging the entire heart with contiguous slices in the short-axis orientation assures that
the extent of infarcts or severe injury can be accurately assessed.
15. Inject the contrast agent and take note of time. Wait now ≥1 min before starting to
optimize the inversion time (TI). This requires acquiring images for a series of
different TI values, and determining the TI that will result in nulling of signal from
normal myocardium. TI can be set 5% to 10% higher than the optimal value to
Table A11.3.5 Primary Clinical Imaging Parameters for Sequence 3
(Distribution Volume Assessment)
Patient position Supine
Scan type Rapid segmented 2-D gradient
echo with magnetization
preparation for T1-weighting
Imaging plane (orientation) Double oblique short axis view
Central slice or volume center Centered over the heart
Echo time (TE) <3.5 msec, or as short as possible
Number of lines per segment 23–30
Repeat time (TR) <8 msec, or as short as possible
Inversion time (TI) ∼150–250 msec
Delay time (TD) Adjust to TD to obtain diastolic
images
Flip angle (FA) 15°
Fields of view (FOVx, FOVy) 350 mm, 350r mm, with r = 3/4
(rectangular field of view)
Resolution (∆x, ∆y) 1.37 mm, 1.59 mm
Number of data points collected (Nx, Ny) 256, 220r, with r = 3/4
(rectangular field of view)
(segmented acquisition of phase
encoding steps if possible)
Display matrix (Dx, Dy) 256, 256
Slice thickness (∆z) 6 mm
Number of slices 1; repeated breath-holds for
acquisition of contiguous slices
from base to apex
Slice gap 0.0–0.5 of slice thickness
Number of acquisitions (Nacq) 1
Swap read and phase encoding Only if this reduces aliasing
artifacts and allows reduction of
FOV
Slice location User define short axis locations
between base and apex
Saturation pulses No
Slice series Interleaved
ECG gating Yes
Scan time 6–12 heart beats
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anticipate the slow, but steady decrease of contrast agent concentration (the half-time
for Gd-DTPA is ∼30 min).
16. Acquire images for slices in the short axis orientation from base to apex using a 6-mm
slice thickness and no gap, or a small gap of <0.2 of slice thickness. Ask the patient
to hold his/her breath for each image acquisition as the sequence for the slice positions
from base to apex is repeated.
For the detection of microvascular obstruction it is necessary to perform the acquisition of
images <5 to 10 min after the injection of contrast agent (Rochitte et al., 1998; Rogers et
al., 1999). The hypoenhancement characeteristic of microvascular obstruction will only
persist for a limited period after which the contrast between non-infarcted tissue and the
zone with microvascular obstruction disappears. Consistent hyperenhancement through-
seg 1
FLASH
IR-pulse
ECG
R
T
RF
TI relaxation delay(1-2 beats) seg 2
IR-pulse
FLASH
R
Segmented Turbo FLASH
Figure A11.3.5 Timing diagram for segmented, ECG-gated gradient echo sequence with inver-
sion recovery preparation for imaging of delayed enhancement. The inversion-recovery preparation
is repeated before acquisition of each segment of phase-encoding lines, and a sufficient delay on
the order of 2 to 3 heartbeats needs to be placed between the inversion pulse and the previous
segment acquisition. The inversion time (TI) is adjusted 1 to 2 min after injection of the contrast
agent to null the signal in normal myocardium.
Figure A11.3.6 Images of early (left) and delayed (right) contrast enhancement in a 65 year old
male patient 4 days after his first acute large anterior myocardial infarction (creatine kinase >7000).
In the images of the early enhancement a dark region in the antero-septal region indicates the
presence of a no-reflow zone. The image acquired with a 10 min delay shows hyperenhancement
in the same area and clearly delineates the extent of the infarction. The images were acquired with
an ECG-gated fast gradient echo sequence with an inversion recovery preparation for maximum
T1-weighting. Blood signal supression was used for better delineation of the endocardial border,
and images were acquired at end-diastole. Images courtesy of Drs. João Lima and Bernhard
Gerber, Johns Hopkins Medical Institution, Baltimore.
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out the entire infarct zone has been reported in studies where contrast enhancement was
measured 20 to 30 min after injection of the contrast agent (Kim et al., 1999). Figure
A11.3.6 shows images during early (<1 to 2 min post-injection) and delayed enhancement
(∼10 min post-injection) acquired in a patient with myocardial infarct in the anterior wall.
Figure A11.3.7 shows images in another patient acquired ∼30 min after contrast agent
injection with the sequence and parameter settings described in Table A11.3.5.
Gadopentetate dimeglumine (Gd-DTPA) has been the predominantly used contrast agent
for studies of myocardial viability. Hyperenhancement of injured and non-viable myocar-
dial tissue reflects an increased volume of distribution compared to normal myocardium.
With protein-binding contrast agents the hyperenhancement in injured and/or non-viable
myocardium may not only reflect an increase of the distribution volume but also a change
of the contrast agent relaxivity with binding to proteins released after myocardial injury.
Process data and view for sequence 3
17. View images of delayed contrast enhancement with an identical window-setting for
all slices. A simultaneous display of images for all slices is recommended for a visual
assessment of the extent of contrast hyperenhancement.
18. Software with simple planimetric measurement tools is useful to quantify the extent
of myocardial regions with contrast hyperenhancement. Determine the signal inten-
sity in the region with hyperenhancement and in a remote region. Measure the relative
area of hyperenhancement in each slice.
COMMENTARY
Background Information
Coronary artery diseases remain the most
common cause of death for Americans. It is
estimated that this year 1,100,000 Americans
will suffer a new or recurrent myocardial in-
farction. Over 40% of people who experience
a myocardial infarction in a given year will die
from it. It is estimated that the economic cost
of coronary artery disease in the United States
was $118.2 billion in 1999. While nuclear
medicine and echocardiography tests remain
the primary imaging modalities for assessing
the presence of myocardial ischemia and viabil-
ity, each test suffers from limitations of spatial
resolution and artifacts. First-pass MRI perfu-
sion imaging is emerging as a very capable
Figure A11.3.7 Images of delayed contrast enhancement obtained in a 49-year-old male with a
history of two myocardial infarctions—one  myocardial infarction (MI) four years before MRI followed
by percutaneous transluminal coronary angioplasty (PTCA) and stent to his right coronary artery
(RCA). The images shown in the figure were acquired 2.5 months after a second, anterior wall MI
and subsequent coronary artery bypass graft (CABG) surgery. Gadolinium DTPA of 40 ml was used
and imaging was performed ∼30 min after contrast injection with a segmented turbo FLASH
sequence as shown in Fig. A11.3.5. Images provided by Dr. R. White, Cleveland Clinic Foundation.
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alternative for non-invasive assessment. The
excellent spatial resolution of MRI allows for
the detection of subendocardial ischemia. This
is not possible with other tests and explains, in
part, why some studies reported better sensitiv-
ity and specificity with MRI than other non-in-
vasive imaging tests.
While the first pass of gadolinium contrast
agent is useful for the detection of ischemia,
late enhancement of the myocardium identifies
injured myocardium, infarct, and scar. It can be
used to effectively assess viable myocardium.
Late enhancement combined with the detection
of wall motion abnormalities by MR cine ap-
pears to be highly effective in establishing a
cardiac cause for chest pain in an emergency-
room setting.
Critical Parameters and
Troubleshooting
First pass image quality is limited by signal-
to-noise ratio. Thus, it is advantageous to use a
phase-array torso coil. As the sensitivity profile
of these coils is less at the lateral wall of the left
ventricle than the interventricular septum or
anterior wall, signal in the lateral wall needs to
be normalized not to mistake it for ischemia.
This can be corrected by acquiring calibration
images with the surface coil or the body coil as
receive elements, respectively. Calibration im-
ages should be acquired for the same slice
locations and fields of view as used for the
perfusion study. Comparison of the signal in-
tensity in the two calibration images for iden-
tical region of interest (ROI) locations allows
accurate determination of the scaling factors
that normalize the signal intensity curves to a
common standard. Susceptibility changes with
the passage of contrast through the heart can
produce apparent subendocardial perfusion de-
fects that are artifactual. These appear predomi-
nantly in the read direction and are more severe
with longer TE. These artifacts tend not to per-
sist as long as true ischemic changes and can
be accounted for with experience.
Better SNR is achievable at higher doses of
gadolinium-based contrast agent. However, the
high concentration of contrast media in the
blood will result in saturation of signal and
eliminates the potential for quantitative analy-
sis. The authors find that 0.03 to 0.05 mmol/kg
of Gd-DTPA provides adequate SNR with
minimal saturation effects. It is possible to
repeat the injection if necessary to either in-
crease the coverage of the left ventricle or to
obtain a stress set of images in addition to the
baseline. Antecubital injections at 5 to 8 ml/sec
provide a satisfactory bolus in most patients.
Adequate coverage of the left ventricle for
first pass imaging requires at least three 1-cm
slices in the short axis. The number of slices
that can be obtained in a sequence depends on
both the minimum TR and the heart rate. Like-
wise, the spatial resolution (number of phase
encoding steps) is inversely related to the tem-
poral resolution. Thus, for fast heart rates, it
may be necessary to obtain an image of every
other heart beat in order to obtain adequate
spatial resolution.
Optimal detection of myocardial ischemia
depends on achieving maximal hyperemia.
This may be accomplished with either adeno-
sine or dipyramidole. It is vital to monitor the
blood pressure to avoid hypotension. Addition-
ally, it is important to remain in close commu-
nication with the patient to assess chest pain or
dyspnea. If any of these conditions present, the
drug is immediately discontinued and appro-
priate therapy is given.
A higher dose of contrast agent is commonly
used for studies of enhancement. Good results
have been obtained with 0.1 mmol/kg of Gd-
DTPA. It is recommended to image 3 to 15 min
after injection.
Anticipated Results
Visual inspection of first pass perfusion im-
ages can identify ischemic zones in many pa-
tients. As indicated above, it is important to
assure that a dark zone is not an artifact by
verifying that it persists for more than a few
seconds. Even greater sensitivity may be
achieved by the use of quantitative methods that
model the tissue perfusion.
Delayed enhancement of infarcted myocar-
dium appears to be robust and a number of
groups have excellent results with this simple
test. There does remain some controversy as to
whether all hyperenhanced myocardium is in
fact non-viable (Rogers et al., 1999). Neverthe-
less, in the appropriate setting, this is a very
useful test.
Data processing and viewing of perfusion
images
Region of interest analysis is very useful to
generate time courses for the signal intensity
that facilitate the interpretation of regional con-
trast enhancement (Wilke et al., 1993).
Changes in signal intensity from image to im-
age are assumed to reflect changes in contrast
agent residue concentration but this interpreta-
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tion applies rigorously only under special con-
ditions (Burstein et al., 1991). The resulting
curves of signal intensity versus time can be
compared for different myocardial ROI’s to
compare the kinetics of contrast agent wash-in
(Jerosch-Herold et al., 1999; Kroll et al., 1996).
The initial increase in signal intensity during
wash-in of the contrast agent represents the
portion of the signal curves that is most sensi-
tive to changes in myocardial blood flow
(Jerosch-Herold et al., 1998; Kroll et al., 1996).
Several semi-quantitative parameters may be
used to characterize the contrast agent up-take.
Examples are the up-slope of the signal curve
during the contrast agent wash-in, which is
indicative of the rate of contrast agent up-take,
and the peak amplitude during the first pass that
provides a relative measure of the peak concen-
tration of contrast agent in a tissue region. With
a compact bolus, as can be achieved by central
injection of the contrast agent, the maximum
amplitude of the tissue curves is indicative of
the level of tissue perfusion, i.e., blood flow.
This correlation of the peak amplitude with
blood flow becomes weaker as the bolus dura-
tion is increased, and the up-slope correlates
more closely with relative changes of tissue
blood flow when the bolus is intravenously
injected (Bassingthwaigthe et al., 1993).
Calculation of semi-quantitative parameters
needs, in general, to be performed “off-line” on
a personal computer or workstation with appro-
priate analytical software to analyze the signal
curve characteristics. Semi-quantitative perfu-
sion parameters such as the up-slope of the
signal intensity curve are best determined from
a smooth approximation to the measured data.
This requires the use of some sort of model that
is fit to the measured data. Figure A11.3.8
shows an example where a model of the impulse
response was used for convolution with the
measured “input” function in the left ventricle
to calculate a tissue curve. The model parame-
ters were adjusted to the measured data by using
a least squares fitting algorithm.
A simple approach to obtaining a smooth
approximation to the measured data consists of
performing a nonlinear least squares fit of a
gamma-variate function to the first pass of the
measured data. From the fit of the gamma-vari-
ate function to the measured data, only the
portion of the signal curve before appearance
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Figure A11.3.8 Signal intensity curves from regions of interest (ROI) in a series of perfusion
images, that is also shown in Fig. A11.3.4. The signal intensity curves correspond to the basal slice
position. The dashed line represents the signal changes in for an ROI in the center of the left
ventricular (LV) cavity. The signal curves with open circles and triangles were obtained for transmural
ROI’s in the anterior and posterior segments, respectively. Signal curves were scaled to correct for
inhomogeneity of sensitivity profile of the receiver coil. Relevant parameters for assessing perfusion
in a semiquantitative manner are the up-slope during contrast agent wash-in, and the peak
amplitude. The definition of these two parameters is illustrated in the inset of this figure. Perfusion
in the inferior/posterior wall segment was abnormally low in this patient.
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of the recirculation can be used. The recircula-
tion of tracer often can not be clearly identified
in tissue curves and the reappearance of con-
trast agent in the left ventricle should then be
used as a “cut-off” criterion. Many graphing
and data analysis programs for personal com-
puters offer the option of fitting the data to a
user-defined function, such as a gamma-variate
function, with a non-linear least squares algo-
rithm. A rigorous analysis of the curves with
tracer kinetic models is possible if the MRI
protocol is set up such that the signal intensity
can provide an accurate measure of the contrast
agent concentration in blood and tissue regions.
Tracer kinetic modeling generally requires the
use of an arterial input function. The signal time
course for an ROI in the left ventricle is often
chosen as an approximation for this purpose.
For further details on modeling of myocardial
perfusion the reader is referred to the literature
(Jerosch-Herold and Wilke, 1997; Jerosch-
Herold et al., 1999; Kroll et al., 1996; Wilke
and Jerosch-Herold, 1998).
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for imaging of myocardial perfusion and viability.
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